Clinical trials located in

Le Havre

Le Havre city is located in France. Currently, 5 clinical trials are being conducted in this city.

Le Havre, located in northern France, is a notable port city on the English Channel. Founded in 1517 by King Francis I, it has evolved into France’s second-largest port. The city was extensively rebuilt under the guidance of architect Auguste Perret after World War II, leading to its recognition as a UNESCO World Heritage site for its innovative use of concrete in architecture. Le Havre is also the birthplace of impressionist painter Claude Monet, highlighting its rich cultural heritage. The city’s modernist architecture contrasts with its historical roots, making it a unique blend of the old and new.

  • CT-EU-00057871

    Deucravacitinib: A possible solution for active Sjögren’s Syndrome

    The study aims to evaluate the effectiveness and safety of the medication Deucravacitinib, also known as BMS-986165, in adults diagnosed with Active Sjögren’s Syndrome, a condition characterized by symptoms like dry eyes and mouth. The study is designed to understand how well Deucravacitinib can alleviate these symptoms compared to a placebo. This is done over a series of regular checks over time to monitor the improvement in symptoms and the overall safety of the medication for participants.

    Deucravacitinib will be given in two different doses to different groups of participants to determine which dose is more effective. Those on the placebo will later receive one of the doses of Deucravacitinib. The study will assess changes in various symptoms and measures of disease activity at several points during the study, providing insights into both the short-term and longer-term effects of the treatment.

    Throughout the study, participants will have their symptoms monitored and will undergo various assessments to see if there is any improvement in their condition and to check for any possible side effects from the medication. This includes checking the severity of their symptoms, overall health, and any changes in their body’s response to the treatment.

    • Deucravacitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France: